Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
Florian P. Reiter(LMU Klinikum), Enrico N. De Toni(LMU Klinikum)
Cited by 24
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
|Cell Death Discovery|2019|60
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
|Liver Cancer|2023|44